Here are four highlights:
1. North American leads the market due to a high incidence of sepsis and more public awareness about sepsis complications. Sepsis infected 1.16 million U.S. residents annually last year.
2. A growing incidence rate and increased sepsis research is fueling European growth.
3. Factors spurring expansion include a higher prevalence of hospital-acquired infections and an increasing surgical demand.
4. Companies operating in the market include:
● Adrenomed
● Altor BioScience Corp.
● Boehringer Ingelheim
● Bristol-Myers Squibb Co.
● InflaRx
● Inotrem
More articles on quality and infection control:
Theranos paying Arizona residents $4.65M, won’t operate lab for two years: 4 key notes
WHO Surgical Safety Checklist reduces postsurgical deaths: 2 study insights
HAI control market to surpass $82.9B by 2020 at 8.5% CAGR: 5 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.